Clinical Evaluation of the Effect of Pyridinolcarbamate (Anginin) on Ischemic Heart Diseases

概要

論文の詳細を見る
1) In 15 cases of ischemic heart disease (5 cases of type I of the WHO classification, 6 cases of type III and 4 cases of type IV), pyridinolcarbamate (Anginin) (750 to 2, 250mg./day) was given orally for 2 to 6 weeks to determine the effect. 2) In subjective symptoms, a positive effect was obtained in 9 of 11, while 4 of 14 showed a positive effect in ECG findings (cases without symptoms or findings before administration were excluded). In type I (WHO classification) subjective symptoms improved in all of the 5 cases, and ECG findings improved in 3 cases. In type III, on the other hand, subjective symptoms improved in 4 of 6 but ECG findings improved only in 1. No effect was seen in 4 cases of type IV. 3) As side effects, headache and a sensation of chest compression were seen in one case each. No other side effects were seen under the experimental conditions of the present study.
International Heart Journal刊行会の論文